MARATTO

review · JCO Precision Oncology

Impact of <i>BRCA</i> Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis

20253 citationsAlexandria University

Abstract

The current analysis adds to the body of evidence supporting the inferior outcomes of ET± CDK4/6i in <i>BRCA MT</i> compared with <i>BRCA WT</i>. Given its significant coexistence with <i>RB1</i> LOH, <i>BRCA2 MT</i> BC seems uniquely resistant to ET± CDK4/6i, a point that is profoundly different from sporadic or even <i>BRCA1 MT</i> HR+/HER2- BC.

Research topics

  • Advanced Breast Cancer Therapies
  • BRCA gene mutations in cancer
  • Breast Cancer Treatment Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1200/po-24-00841

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.